3878
Inorg. Chem. 1996, 35, 3878-3880
Synthesis and Characterization of a Boronated Metallophthalocyanine for Boron Neutron
Capture Therapy
Stephen B. Kahl* and Jing Li
Department of Pharmaceutical Chemistry, University of California,
San Francisco, California 94143-0446
ReceiVed January 10, 1996X
Synthesis of the first fully characterized, water-soluble boronated phthalocyanine is reported. Reaction of
4-nitrophthalonitrile with dimethyl malonate in the presence of base yielded dimethyl (3,4-dicyanophenyl)malonate
which was converted into dimethyl (3,4-dicyanophenyl)propargylmalonate by sequential treatment with potassium
hydroxide and propargyl bromide. Formation of the o-carborane cage was accomplished by reaction of the alkyne
with decaborane in acetonitrile at reflux. High-temperature solid state condensation of the resulting o-
carboranylphthalonitrile with cobalt(II) chloride followed by ester deprotection and cation exchange provided the
water-soluble closo-carbonylphthalocyanine product. The product contains 40 boron atoms (27% boron by weight)
and may be useful as a tumor-seeking boron delivery agent for boron neutron capture therapy of cancer.
was purchased from Dexsil Corp. and was sublimed prior to use. All
other reagents and chemicals were purchased from Aldrich, and all
reactions were carried out under high-purity argon unless otherwise
indicated. High-resolution mass spectra (HRMS) were recorded on a
VG-70SE mass spectrometer in EI mode for molecules less than 900
amu. Liquid secondary ion mass spectra (LSIMS) were recorded in a
nitrobenzyl alcohol matrix on a VG-70SE mass spectrometer for
molecules of more than 1000 amu. Infrared (IR) spectra were recorded
on a Nicolet Impact 400 infrared spectrophotometer using KBr disks.
Nuclear magnetic resonance (NMR) spectra for proton and carbon were
recorded on a GE 300 NMR spectrometer with TMS as an internal
standard. Ultraviolet-visible spectra (UV-vis) were recorded on a
HP8452A diode array spectrophotometer. Melting points (mp) were
measured by a Thomas Hoover capillary melting point apparatus and
are uncorrected. Chromatography was performed with silica gel (Merck
grade 60) from Aldrich. Microanalyses were performed by the
Microanalysis Laboratory of College of Chemistry, University of
California, Berkeley, CA.
Dimethyl (3,4-Dicyanophenyl)propargylmalonate, 4. To a sus-
pension of compound 3 (3 g, 0.01 mol) in acetone (70 mL) was added
propargyl bromide (1.8 g, 80% in toluene, 0.012 mol). The suspension
was stirred and heated to reflux under argon for 20 h. The potassium
bromide precipitate was filtered off and acetone was removed in Vacuo
to give an oily residue. Chromatography of the oily residue using
hexane/THF (6:1) as the eluant generated 2.4 g (83%) of dimethyl (3,4-
dicyanophenyl)propargylmalonate 4 (mp: 90-91 °C). HRMS for
C16H12N2O4 (M+): calcd, 296.0797; found, 296.0789 (∆ ) 0.8 ppm).
1H NMR (CDCl3-d1): δ 8.02 (d, J ) 1.5 Hz, H), 7.89, 7.87 (2dd, J )
1.5 Hz, J ) 8.4 Hz, H), 7.81 (d, J ) 8.4 Hz, H), 3.84 (s, 6H), 3.23 (d,
J ) 2.4 Hz, 2H), 2.09 (t, J ) 2.4 Hz, H). 13C NMR (CDCl3-d1): δ
168.1, 141.2, 138.1, 133.9, 133.2, 133.1, 115.7, 115.2, 115.0, 114.9,
73.5, 61.6, 53.8, 25.7. IR (KBr disk): 2240 cm-1 (CN), 1733 cm-1
(CdO).
Introduction
Boron neutron capture therapy (BNCT) is a binary method
for cancer therapy which allows selective tumor irradiation. The
principle of BNCT is based on the interaction of a nonradioac-
tive 10B nucleus with low-energy (thermal) neutrons to generate
4
7
cytotoxic particles, He and Li, of ∼2.3 MeV kinetic energy.
These fission fragments have mean free paths approximately
equivalent to the average cell diameter, thus confining their
considerable radiation damage to the immediate vicinity of cells
in which they are located.1 It has been calculated that a
minimum cellular 10B concentration of between 10 and 30 µg
per gram of tumor is necessary for clinically effective BNCT.1
The challenge for chemists, therefore, is to synthesize 10B-
containing compounds capable of specific localization and
retention in tumor cells at or above these levels while simul-
taneously clearing normal, nontarget tissues and blood. Certain
phthalocyanines (Pc’s) have been proven to localize and persist
in various solid tumors, and metallophthalocyanines have been
used, in Vitro and in ViVo, as photosensitizers for photodynamic
therapy (PDT).2,3 Thus, the use of a metallophthalocyanine to
deliver 10B atoms to a tumor might be a viable strategy for
meeting this challenge. Phthalocyanines usually exhibit notori-
ous insolubility in both water and organic solvents that precludes
adequate purification and characterization, so the key issue is
to synthesize a boronated phthalocyanine having both lipophilic
and hydrophilic substituents capable of enhancing the solubility
of boronated phthalocyanines in therapeutic solutions. The first
water-soluble boronated phthalocyanine, bearing only one closo-
carborane cage, was synthesized by Soloway et al.4 However,
no detailed information on its purification and characterization
was reported.
Dimethyl (3,4-dicyanophenyl)(o-carboranylmethyl)malonate, 6.
To a two-necked round-bottomed flask charged with B10H14, 5 (0.82
g, 0.0067 mol), was added 50 mL of anhydrous acetonitrile by syringe.
The solution was heated to reflux under argon for 1 h and then allowed
to cool to room temperature. Compound 4 (2.0 g, 0.0067 mol) was
added, and the resulting solution was futher refluxed under argon for
40 h or until TLC analysis indicated that no compoud 4 could be
observed in the solution. Acetonitrile was evaporated in Vacuo to give
a waxy white solid. The solid was dissolved in a small volume of
methanol and then adsorbed on a small portion silica gel and loaded
onto a silica gel column which was eluted with hexane and THF (4:1).
The first fraction was collected to give 1.4 g of the desired product 6
Experimental Section
Dimethyl (3,4-dicyanophenyl)malonate, 2, and its potassium salt,
3, were synthesized according to literature procedures.5 4-Nitrophtha-
lonitrile was purchased from Tokyo Chemical Inc. (TCI). Decaborane
X Abstract published in AdVance ACS Abstracts, June 1, 1996.
(1) Hawthorne, M. F. Angew. Chem., Int. Ed. Engl. 1993, 32, 950.
(2) van Lier, J. E. In Photodynamic Therapy of Neoplastic Disease; Kessel,
D., Ed.; CRC Press: Boca Raton, FL, 1990; Vol. 1, p 279.
(3) Rosenthal, I. Photochem. Photobiol. 1991, 31, 102.
(4) Alam, F.; Soloway, A. H.; Bapat, B. V.; Barth, R. E.; Adams, D. M.
Basic Life Sci. 1989, 50, 107.
(5) Roze, M. P.; Berzin’sh, E. L.; Neiland, O. Ya. Zh. Org. Khim. 1992,
28, 827.
S0020-1669(96)00024-9 CCC: $12.00 © 1996 American Chemical Society